Marker Therapeutics, Inc. (MRKR) stock
Close on Nov 11, 2026Market cap $15.84MP/E –Yield –
Marker Therapeutics, Inc. saw revenue fall 46.2% to $3.55M over fiscal 2025. At the latest close the market valued the company at $15.84M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $15.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.55M
- Net income
- -$8.71M
- EPS, diluted
- -$0.46
- Book value per share
- $0.63
- Diluted shares
- 19M
Trading
- Previous close
- $0.95
- Open
- $0.95
- Day's range
- $0.94 – $0.98
- Volume
- 28,409
- Average volume (20 days)
- 198,889
- Beta (5 years)
- 1.28
- 52-week range
- $0.87 – $2.46
- RSI (14 days)
- 46.0
- Volatility (1 year)
- 84.4%
- Relative volume
- 0.28×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MRKR | S&P 500 | Difference | MRKR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.2% | -2.4% | +0.2 pts | ||
| 3 months | -15.2% | -1.2% | −14.0 pts | ||
| Year to date | -36.2% | +12.3% | −48.5 pts | ||
| 1 year | +2.0% | +12.4% | −10.5 pts | ||
| 3 years | -65.1% | +78.8% | −143.9 pts | -29.6% | +21.4% |
| 5 years | -93.3% | +75.2% | −168.5 pts | -41.8% | +11.9% |
| 10 years | -98.0% | +311.1% | −409.1 pts | -32.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Marker Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- News
- News
- Update
About Marker Therapeutics
Pharmaceutical Preparations
Marker is a clinical-stage immuno-oncology company developing novel T cell-based immunotherapies for hematological cancers and solid tumors. The company focuses on its Multi-Antigen Recognizing T cell platform, which expands natural, non-genetically modified tumor-specific T cells from blood to target multiple antigens simultaneously. Its pipeline features lead autologous candidate MT-601, evaluated for relapsed lymphoma and pancreatic cancer, and off-the-shelf candidate MT-401-OTS for acute myeloid leukemia and myelodysplastic syndromes. Marker serves patients with advanced cancer indications, particularly those with relapsed disease or limited alternatives.
Company profile, executives and historyMarker Therapeutics stock: common questions
What is Marker Therapeutics's stock price?
MRKR closed at $0.95 on Nov 11, 2026, down 0.02% on the day. Over the past 52 weeks it traded between $0.87 and $2.46.
What is Marker Therapeutics's market cap?
Marker Therapeutics was worth $15.84M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MRKR's P/E ratio?
Marker Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
How much revenue does Marker Therapeutics make?
Marker Therapeutics reported revenue of $3.55M for fiscal 2025, down 46.2% from a year earlier.
Does Marker Therapeutics pay a dividend?
No. Marker Therapeutics has not paid a cash dividend over the last twelve months.
How has MRKR stock performed over the past year?
Including dividends, MRKR returned +2.0% over the past year, against +12.4% for the S&P 500.
How many MRKR shares are sold short?
0M shares were sold short at the latest FINRA report, 1.55% of the float, or 1.0 days of average trading volume.
Who are Marker Therapeutics's competitors?
Companies most similar to Marker Therapeutics by business, industry and size include IMNM, BOLT, TCRX, XBIO, HCWB.
See a number that looks wrong?